共 50 条
- [41] Phase Ib/II study combining the HDAC inhibitor domatinostat with anti-PD-1 pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapyJOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18Ascierto, Paolo A.Hassel, Jessica C.Berking, CarolaEigentler, ThomasGutzmer, RalfSchilling, BastianHermann, FrankBartz, ReneSchadendorf, Dirk
- [42] Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II studyANNALS OF ONCOLOGY, 2018, 29Diab, A.Haymaker, C.Bernatchez, C.Andtbacka, R. H. I.Shaheen, M.Johnson, D.Markowitz, J.Puzanov, I.Murthy, R.Johnson, D. H.James, M.Chunduru, S.Geib, J.Swann, S.Rahimian, S.Hwu, P.
- [43] Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Coleman, NiamhNaing, AungZhang, ShizhenPiha-Paul, Sarina Anne AnneTsimberidou, Apostolia MariaJanku, FilipRodon, JordiPant, ShubhamDumbrava, Ecaterina ElenaFu, SiqingHong, David S.Meric-Bernstam, FundaSubbiah, Vivek
- [44] Phase Ib/II study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Razak, Albiruni R. A.Ahn, Myung-JuYen, Chia-JuiSolomon, Benjamin J.Lee, Se-HoonWang, Hung-MingMunster, Pamela N.L-Van Herpen, Carla M.Gilbert, JillPal, Rupam RanjanBlumenstein, LarsGomez-Carrillo, BelenCoughlin, Christina MarieLim, Wan-Teck
- [45] Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Benson, Don M.Kahl, Brad S.Furman, Richard R.Brown, Jennifer R.Wagner-Johnston, Nina D.Coutre, Steven E.Spurgeon, Stephen Edward ForbesByrd, John C.Leonard, JohnPeterman, SissyJohnson, David MichaelCho, YoonjinDansey, Roger D.Godfrey, Wayne R.Flinn, Ian
- [46] Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell LymphomaCANCERS, 2020, 12 (08) : 1 - 14Huen, AurisHaverkos, Bradley M.Zain, JasmineRadhakrishnan, RamchandrenLechowicz, Mary JoDevata, SumanaKorman, Neil J.Pinter-Brown, LaurenOki, YasuhiroBarde, Prajak J.Nair, AjitRouthu, Kasi ViswanathViswanadha, SrikantVakkalanka, SwaroopIyer, Swaminathan P.
- [47] A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Forero-Torres, AndresBarr, Paul M.Diefenbach, Catherine S. MagidSher, TaimurSchaub, RichardZhou, LiPulini, JenniferLeopold, LanceSpear, Matthew A.Talpaz, MoshePhillips, Tycel Jovelle
- [48] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Baselga, J.De Jonge, M. J.Rodon, J.Burris, H. A., IIIBirle, D. C.De Buck, S. S.Demanse, D.Ru, Q. C.Goldbrunner, M.Bendell, J. C.
- [49] Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Spurgeon, Stephen Edward ForbesWagner-Johnston, Nina D.Furman, Richard R.Flinn, IanCoutre, Steven E.Brown, Jennifer R.Benson, Don M.Byrd, John C.Leonard, JohnPeterman, SissyJohnson, David MichaelGu, JessieDansey, Roger D.Godfrey, Wayne R.Kahl, Brad S.
- [50] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Papadopoulos, K. P.Markman, B.Tabernero, J.Patnaik, A.Heath, E. I.DeCillis, A.Laird, D.Aggarwal, S. K.Nguyen, L.LoRusso, P. M.